Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients-Reference-Cited by-同舟云学术

Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients

Published:2012-01-18 Issue:117 Volume:4 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Clark Rachael A.¹²,Watanabe Rei¹,Teague Jessica E.¹,Schlapbach Christoph¹,Tawa Marianne C.²,Adams Natalie²,Dorosario Andrew A.²,Chaney Keri S.¹,Cutler Corey S.²,LeBoeuf Nicole R.¹,Carter Joi B.³,Fisher David C.²,Kupper Thomas S.¹²

Affiliation:

1. Department of Dermatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA.

2. Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA 02115, USA.

3. Department of Dermatology, Massachusetts General Hospital, Boston, MA 02114, USA.

Abstract

Alemtuzumab depletes malignant T cells but spares skin resident effector memory T cells, treating L-CTCL without increased risk of infection.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference51 articles.

1. WHO-EORTC classification for cutaneous lymphomas

2. Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome

3. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas (National Comprehensive Cancer Network Fort Washington PA 2009).

4. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome

5. Oncogenomic analysis of mycosis fungoides reveals major differences with Sézary syndrome

Cited by 306 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides;Nature Communications;2024-01-25

2. Research progress on intestinal tissue‐resident memory T cells in inflammatory bowel disease;Scandinavian Journal of Immunology;2023-10-17

3. Cutaneous immune‐related adverse events from immune checkpoint inhibitor therapy: Moving beyond “maculopapular rash”;Immunological Reviews;2023-08-15

4. Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study;Blood Advances;2023-08-11

5. Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy;Frontiers in Immunology;2023-07-20